Treatment Information

Back

Kidney (Renal) Cancer treatment details. Immunotherapy.

University of Texas M. D. Anderson Cancer Center, Houston, TX, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Houston, TX
Treatments:ImmunotherapyHospital:University of Texas M. D. Anderson Cancer Center
Drugs:Journal:Link
Date:Jul 2008

Description:

Patients: This phase II study involved 44 patients with metastatic renal cell carcinoma (kidney cancer). The median age was 64 years, and the majority (64%) of patients were men.

Treatment: Patients were treated with talactoferrin, an immunotherapy.

Toxicities: There was one report of grade 3 dyspnea. Other toxicities were grade 1 or 2, and included fatigue, flatulence, abdominal pain, and diarrhea.

Results: The median overall survival was 21.1 months.

Support: This study was supported by reseach funds from Agennix, Inc., which developed/owns talactoferrin.

Correspondence: Dr. Eric Jonasch





Back